Trial Outcomes & Findings for The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure (NCT NCT05346653)
NCT ID: NCT05346653
Last Updated: 2024-09-04
Results Overview
Measured by pulmonary artery catheter
Recruitment status
TERMINATED
Study phase
PHASE4
Target enrollment
1 participants
Primary outcome timeframe
4 days
Results posted on
2024-09-04
Participant Flow
Participant milestones
| Measure |
SGLT2i
Participants will be treated with a SGLT2i during their ICU stay. The SGLT2i and heart failure care will be managed according to routine care, and data will be collected from the participant's medical record.
SGLT2i: dapagliflozin (10 mg daily)
|
No SGLT2i
Participants will not be treated with a SGLT2i during their ICU stay. Heart failure care will be managed according to routine care, and data will be collected from the participant's medical record.
No SGLT2i: No SGLT2i
|
|---|---|---|
|
Overall Study
STARTED
|
0
|
0
|
|
Overall Study
COMPLETED
|
0
|
0
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure
Baseline characteristics by cohort
Baseline data not reported
PRIMARY outcome
Timeframe: 4 daysPopulation: Only 1 subject consented to the study and was not eligible for randomization.
Measured by pulmonary artery catheter
Outcome measures
Outcome data not reported
PRIMARY outcome
Timeframe: 4 daysPopulation: Only 1 subject consented to the study and was not eligible for randomization.
Measured by pulmonary artery catheter
Outcome measures
Outcome data not reported
Adverse Events
SGLT2i
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
No SGLT2i
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place